Home > Archive>Volume 15, Issue 4, 2022 >591-597. DOI:10.18240/ijo.2022.04.11
PDF HTML XML Export Cite reminder
Preoperative laser reduces silicone oil use in primary diabetic vitrectomy
Author:
Corresponding Author:

Tao Li. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University; #7 Jinsui Road, Guangzhou 510060, Guangdong Province, China. litao2@mail.sysu.edu.cn

Fund Project:

Supported by the National Natural Science Foundation of China (No.82070972); the Natural Science Foundation of Guangdong Province (No.2019A1515011347); the grants from the Guangdong Province High-level Hospital Construction Program (No.303020103); the Key Science&Technology Project of Guangzhou (No.202103000045).

  • Article
    • | |
  • Metrics
    • |
  • Reference [32]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    AIM: To identify the predictive factors and laser photocoagulation associated with the use of silicone oil as endotamponade during primary diabetic vitrectomy. METHODS: The medical and surgical records of 690 patients (798 eyes) who underwent primary diabetic vitrectomy at a tertiary eye hospital in China from January 2018 to December 2018 were reviewed in this retrospective cohort study. The patients’ baseline characteristics and preoperative treatments were recorded. The binary Logistic regression model was used to evaluate the risk factors for the use of silicone oil as endotamponade agent during primary vitrectomy for proliferative diabetic retinopathy (PDR)-related complications. RESULTS: Among 690 patients with mean age of 52.1±10.5y (range: 18-85y), 299/690 (43.3%) were female. The 31.6% of the eyes received preoperative laser treatment, and 72.4% of the eyes received preoperative anti-VEGF adjuvant therapy. Non-clearing vitreous haemorrhage (VH) alone or combined with retinal detachment was the main surgical indication (89.5%) for primary vitrectomy. Silicone oil was used as endotamponade in 313 (39.2%) eyes. Lack of preoperative laser treatment [odds ratio (OR) 0.66, 95% confidence interval (CI): 0.48-0.92; P=0.015] and older age (OR 0.96, 95%CI: 0.95-0.98; P<0.001) were predictors of silicone oil tamponade during primary vitrectomy for PDR. CONCLUSION: The lack of preoperative laser treatment is a significant predictor of silicone oil tamponade during primary vitrectomy for PDR. However, the severity of PDR relevant to silicone oil use should be further evaluated.

    Reference
    1 Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376(9735):124-136.
    2 Yau JWY, Rogers SL, Kawasaki R, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35(3):556-564.
    3 Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R, Committee IDFDA. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019;157:107843.
    4 Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5 Suppl):766-785.
    5 Flynn HW Jr, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL 3rd. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1992;99(9):1351-1357.
    6 Castellarin A, Grigorian R, Bhagat N, del Priore L, Zarbin MA. Vitrectomy with silicone oil infusion in severe diabetic retinopathy. Br J Ophthalmol 2003;87(3):318-321.
    7 Aaberg TM. Pars plana vitrectomy for diabetic traction retinal detachment. Ophthalmology 1981;88(7):639-642.
    8 Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Diabetic retinopathy preferred practice pattern®. Ophthalmology 2020;127(1):P66-P145.
    9 Parikh HA, Kalbag NS, Zarbin MA, Bhagat N. Characteristics, demographics, outcomes, and complications of diabetic traction retinal detachments treated with silicone oil tamponade. Eur J Ophthalmol 2016;26(5):497-502.
    10 Jabbour E, Azar G, Antoun J, Kourie HR, Abdelmassih Y, Jalkh A. Incidence and risk factors of ocular hypertension following pars plana vitrectomy and silicone oil injection. Ophthalmologica 2018;240(3):129-134.
    11 Morphis G, Irigoyen C, Eleuteri A, Stappler T, Pearce I, Heimann H. Retrospective review of 50 eyes with long-term silicone oil tamponade for more than 12 months. Graefes Arch Clin Exp Ophthalmol 2012;250(5):645-652.
    12 Kohanim S, Sternberg P Jr. Ophthalmic patient data registries: defining and improving quality and outcomes. Ophthalmology 2014;121(3): 619-621.
    13 Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaveri CD, Punjabi OS, Salehi-Had H, Wells JA 3rd, 3rd M, Stockdale CR, Martin DF, Sun JK, Network DRCRR. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2020;324(23):2383-2395.
    14 Iyer SSR, Regan KA, Burnham JM, Chen CJ. Surgical management of diabetic tractional retinal detachments. Surv Ophthalmol 2019;64(6): 780-809.
    15 Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch Ophthalmol 1985;103(11):1644-1652.
    16 Stewart MW, Browning DJ, Landers MB. Current management of diabetic tractional retinal detachments. Indian J Ophthalmol 2018;66(12):1751-1762.
    17 Choovuthayakorn J, Khunsongkiet P, Patikulsila D, Watanachai N, Kunavisarut P, Chaikitmongkol V, Ittipunkul N. Characteristics and outcomes of pars plana vitrectomy for proliferative diabetic retinopathy patients in a limited resource tertiary center over an eight-year period. J Ophthalmol 2019;2019:9481902.
    18 Ramezani A, Ahmadieh H, Rozegar A, Soheilian M, Entezari M, Moradian S, Dehghan MH, Nikkhah H, Yaseri M. Predictors and outcomes of vitrectomy and silicone oil injection in advanced diabetic retinopathy. Korean J Ophthalmol 2017;31(3):217-229.
    19 Zhao XY, Xia S, Chen YX. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials. Br J Ophthalmol 2018;102(8):1077-1085.
    20 Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26(6):699-700.
    21 Khuthaila MK, Hsu J, Chiang A, DeCroos FC, Milder EA, Setlur V, Garg SJ, Spirn MJ. Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy. Am J Ophthalmol 2013;155(4): 757-763.e1-e2.
    22 Kaidonis G, Hassall MM, Phillips R, Raymond G, Saha N, Wong GH, Gilhotra JS, Liu E, Burdon KP, Henderson T, Newland H, Lake SR, Craig JE. Visual outcomes following vitrectomy for diabetic retinopathy amongst Indigenous and non-Indigenous Australians in South Australia and the Northern Territory. Clin Exp Ophthalmol 2018;46(4):417-423.
    23 Schreur V, Brouwers J, van Huet RAC, Smeets S, Phan M, Hoyng CB, de Jong EK, Klevering BJ. Long-term outcomes of vitrectomy for proliferative diabetic retinopathy. Acta Ophthalmol 2021;99(1):83-89.
    24 Chen TT, Jin L, Zhu WH, Wang CY, Zhang GS, Wang XQ, Wang J, Yang K, Cochrane GM, Lamoureux EL, Friedman DS, Gilbert S, Lansingh VC, Resnikoff S, Zhao JL, Xiao BX, He MG, Congdon N. Knowledge, attitudes and eye health-seeking behaviours in a population-based sample of people with diabetes in rural China. Br J Ophthalmol 2021;105(6):806-811.
    25 Xu Y, Wang LM, He J, Bi YF, Li M, Wang TG, Wang LH, Jiang Y, Dai M, Lu JL, Xu M, Li YC, Hu N, Li JH, Mi SQ, Chen CS, Li GW, Mu YM, Zhao JJ, Kong LZ, Chen JL, Lai SH, Wang WQ, Zhao WH, Ning G, China Noncommunicable Disease Surveillance Group 2010. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310(9):948-959.
    26 Ostri C, Lux A, Lund-Andersen H, la Cour M. Long-term results, prognostic factors and cataract surgery after diabetic vitrectomy: a 10-year follow-up study. Acta Ophthalmol 2014;92(6):571-576.
    27 Gupta B, Wong R, Sivaprasad S, Williamson TH. Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice. Eye (Lond) 2012;26(4):576-582.
    28 Uzel MM, Citirik M, Ilhan C, Inanc M. The effect of bevacizumab pretreatment on the choice of endotamponade in diabetic tractional retinal detachment. Ophthalmic Surg Lasers Imaging Retina 2016;47(10):924-929.
    29 Tan YR, Fukutomi A, Sun MT, Durkin S, Gilhotra J, Chan WO. Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: a review. Surv Ophthalmol 2021;66(6):926-932.
    30 Bressler NM, Beaulieu WT, Bressler SB, Glassman AR, Melia BM, Jampol LM, Jhaveri CD, Salehi-Had H, Velez G, Sun JK, Network DRCRR. Anti-vascular endothelial growth factor therapy and risk of traction retinal detachment in eyes with proliferative diabetic retinopathy: pooled analysis of five drcr retina network randomized clinical trials. Retina 2020;40(6):1021-1028.
    31 Chen HJ, Wang CG, Dou HL, Feng XF, Xu YM, Ma ZZ. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy. Ann Palliat Med 2020;9(1):82-89.
    32 Wang DY, Zhao XY, Zhang WF, Meng LH, Chen YX. Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis. Sci Rep 2020;10(1):18880.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Wen-Bin Zheng, Xiao-Hu Ding, Kun-Bei Lai,/et al.Preoperative laser reduces silicone oil use in primary diabetic vitrectomy. Int J Ophthalmol, 2022,15(4):591-597

Copy
Share
Article Metrics
  • Abstract:628
  • PDF: 772
  • HTML: 0
  • Cited by: 0
Publication History
  • Received:June 11,2021
  • Revised:September 28,2021
  • Online: April 18,2022
You are the 4487213 Visitors
Governing Body：Department of Health, Provincial Government of Shaanxi, China
Organizer：Xi'an Medical Association of China
Address：Room 11707-08, Building 2, Unit 1, Wanda Plaza, No.8 Yanta North Road, Xi'an 710054, Shaanxi Province, China
Fax：(8629)82245172 Phone：(+8629)82245172/82210956
Email：ijopress@163.com
International Journal of Ophthalmology ® 2025 All Rights Reserved   The terms of CC BY-NC-ND 4.0 are applicable to all open access content.